皮質醇同型受體表現對於急性淋巴型白血病化療反應之影響及其對策
Date Issued
2005
Date
2005
Author(s)
林凱信
DOI
932314B002206
Abstract
Acute leukemia is the most common childhood malignancy worldwide, and
acute lymphoblastic leukemia (ALL) comprises the majority of pediatric leukemia. It
is well known that the overall prognosis is dependent on the appropriate risk-specific
chemotherapy. Glucocorticoids (GC) have long been the cornerstone of ALL
chemotherapy. A better in vivo response to the initial 7 day prednisolone monotherapy
had correlated to a significantly higher probability of both complete remission and
long-term event free survival (EFS). Unsatisfactory response to GC has led to the
failure of remission induction, and their survival is adversely affected. Glucocorticoid
receptor(GR) expression has long been correlated with GC sensitivity in numerous
experimental systems. Previous studies have suggested that GR-β is a dominant
negative inhibitor, and down-regulation of GR-α or up-regulation of GR-β could
result in GC resistance. Our aim is to determine which mRNA transcript is the one
which accounts for GC resistance.
We collected 35 bone marrow samples from fresh ALL patients. Our results show
the relative expression of GRα、GRβ、GRα/GRβ shows no difference in the 3 risk
groups. The relative expression of GRα、GRβ、GRα/GRβ shows no difference
between the PGR and PPR patients of the 3 risk groups. Furthermore, when they were
divided into two groups ( high and low) according to the median value of the
GRα/GRβ ratio. The prednisolone response, induction remission rate and relapse
rate show no difference in the two groups.
Subjects
acute lymphoblastic leukemia
glucocorticoid receptor
Publisher
臺北市：國立臺灣大學醫學院小兒科
Type
report
File(s)![Thumbnail Image]()
Loading...
Name
932314B002206.pdf
Size
202.6 KB
Format
Adobe PDF
Checksum
(MD5):9a467c3e4b5b566fd93fd69acf62598c